Navigation Links
Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
Date:5/12/2009

ns and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of operations, liquidity and capital resources, financial prospects, business objectives and strategic goals, drug development plans and commercialization strategy, the timing and results of clinical trials and the potential safety and efficacy of the Company's products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market; the Company's research and development activities; the results of preclinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company'
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... an alcohol-based hand sanitizer, asks food processors and food ... the hand sanitizer they’re currently using to Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... Sanitizers believes there are key criteria that make a ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... (Nasdaq: NPSP ) announced today that it ... decision whether to,proceed with ex-U.S. development and commercialization ... expects to receive,notification from Nycomed at the end ... NPS on the development of GATTEX(TM) (teduglutide),outside North ...
... presented at AACR-NCI-EORTC International Conference on ... and Cancer Therapeutics in San Francisco, ... Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a global ... today presented an abstract outlining novel,data generated ...
... antibody uses novel approach to "de-cloak" cancers -, ... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... new findings have been,presented from its Trop-2 and ... Trop-2 and CD59 abstracts at the AACR press,conference ...
Cached Biology Technology:NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... Is television making us fat? An increasing amount of ... food consumption and a more sedentary lifestyle. Now, a ... TV is alike. Some TV programs might lead people ... find that if you,re watching an action movie while ... Aner Tal, Ph.D. lead author on the new article ...
(Date:9/1/2014)... birth, every child in the U.S. undergoes a battery ... including sickle cell disease. Thousands of children born in ... suffer and die from the disease each year. ... at least some of those deaths. , A ... the lab of George Whitesides, the Woodford L. and ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3Zooming in for a safe flight 2
... Sciences, The Pennsylvania State University, State College, Pennsylvania, 12-15 August ... 2012 -- The Society for the Study of Reproduction ... the 45th SSR Annual Meeting to be held in State ... are to be found on the SSR Meeting page ...
... is available in Spanish . The upsurge ... and affects crops in particular. However, Anabel Robredo, a biologist at ... the case of barley at least, climate change itself is providing ... change is in fact also responsible for a considerable increase in ...
... ANGELES (Jan. 25, 2012) The evolutionary processes ... debate. John Torday, Ph.D., a lead investigator ... has recently co-authored a book entitled Evolutionary Biology, ... biology into evolutionary biology. Rather than focusing ...
Cached Biology News:Barley adapts to climate change 2Barley adapts to climate change 3LA BioMed's Dr. John Torday examines evolution from a cellular perspective 2
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... ONE Ribonuclease is a 27kDa periplasmic enzyme ... of RNA to cyclic nucleotide monophosphate (NMP) ... of these intermediates to 3-NMPs (1). RNase ... known RNases that can cleave a phosophodiester ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
...
Biology Products: